Prostaglandin levels in human colorectal mucosa: Effects of sulindac in patients with familial adenomatous polyposis

Digestive Diseases and Sciences

Volumn 43, Issue 2, 1998, Pages 311-316

  Giardiello, Francis M ^a   Spannhake, Ernst W ^b   Dubois, Raymond N ^b   Hylind, Linda M ^b   Robinson, C Rahj ^b   Hubbard, Walter C ^b   Hamilton, Stanley R ^b   Yang, Vincent W ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b NONE

Author keywords

Familial adenomatous polyposis; Nonsteroidal antiinflammatory drugs; Polyps; Prostaglandins; Sulindac

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; SULINDAC; THROMBOXANE B2;

ADENOMATOUS POLYP; ADULT; ARTICLE; CHEMOPROPHYLAXIS; COLON MUCOSA; CONTROLLED STUDY; DRUG EFFECT; FAMILIAL POLYPOSIS; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; RECTUM BIOPSY; RECTUM MUCOSA;

ADENOMATOUS POLYPOSIS COLI; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLON; DINOPROST; DINOPROSTONE; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PROSTAGLANDIN D2; PROSTAGLANDINS; PROSTAGLANDINS F; RECTUM; SULINDAC; THROMBOXANE B2;

EID: 0031893036     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018898120673     Document Type: Article

References (37)

1. Giardiello FM, Offerhaus GJA, DuBois RN: Role of nonsteroidal drugs in colon cancer prevention. Eur J Cancer 31A:1071-1076, 1995
2. Hial V, Demello MC, Horakova Z, Beaven MA: Antiproliferative activity of antiinflammatory drugs in two mammalian cell culture cell lines. J Pharmacol Exp Ther 202:446-454, 1977
3. 1 phase of the cell cycle. Biochem Pharmacol 28:441-443, 1979
4. Bayer BM, Kruth HS, Vaughan M, Beaven MA: Arrest of cultured cells in the G1 phase of the cell cycle by indomethacin. Pharmacol Exp Ther 210:106-111, 1979
5. Pollard M, Luckert PH: Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 64:1323-1327, 1980
6. Moorghen M, Ince P, Finney KJ, Sunter JP, Appleton DR, Watson AJ: A protective effect of sulindac against chemically-induced primary colonic tumors in mice. J Pathol 156:341-347, 1988
7. Skinner SA, Penny AG, O'Brien PE: Sulindac inhibits the rate of growth and development of colon tumors in the rat. Gastroenterology 100:A403, 1990
8. Reddy BS, Rao CV, Rivenson A, Kelloff G: Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14:1493-1497, 1993
9. Jacoby RF, Marshall, Newton MA, Novakovic K, Tutsch K, Cole CE, Lubet RA, Kellof GH, Verma A, Moser AR, Dove WF: Chemoprevention of spontaneous intestinal adenomas in APC Min mouse model by the nonsteroidal antiinflammatory drug piroxicam. Cancer Res 56:710-715, 1996
10. Thun M, Namboodiri M, Heath C: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593-1596, 1991
11. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC: Aspirin use and risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121:241-246, 1994
12. Waddell WR, Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 24:83-87, 1983
13. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas J: Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 115:952-954, 1991
14. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Attali P: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635-639, 1991
15. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJA: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 398:1313-1316, 1993
16. Nugent KP, Farmer KCR, Spigelman AD, Williams DB, Phillips RKS: Randomized controlled clinical trial of sulindac on intestinal polyposis in FAP. Br J Surg 80:1618-1619, 1993
17. Honn KV, Bockmann RS, Marnett LJ: Prostaglandin and cancer a review of tumor initiation through tumor metastasis. Prostaglandin 21:833-864, 1981
18. Jaffe BM: Prostaglandin and cancer: An update. Prostaglandin 6:453-461, 1974
19. 2 and liver lung metastases in colorectal cancer. Dis Colon Rectum 33:840-845, 1990
20. Jaffe BM, Parker CW, Philpott GW: Immunochemical measurement of prostaglandin or prostaglandin-like activity from normal and neoplastic cultured tissue. Surg Forum 22:90-92, 1971
21. Bennett A, Del Tacca M, Stamford IF, Zebro T: Prostaglandin from tumours of human large bowel. Br J Cancer 35:881-884, 1977
22. Tanka M, Nazkazawa S, Koike M: Investigation of endogenous prostaglandin in DMH-induced colonic cancer in rats. J Gastroenterol 82:592-598, 1985
23. Yamaguchi A, Ishida T, Nishimura G, Katoh M, Miyazaki I: Investigation of colonic prostaglandin in carcinogenesis in the rat colon. Dis Colon Rectum 34:572-576, 1991
24. 2. Gut 35:675-678, 1994
25. Earnest DL, Hixson LJ, Finley PR, Backwell GG, Einspahr J, Emerson SS, Alberts DS: Arachidonic acid cascade inhibitors in chemoprevention of human colonic cancer: Preliminary studies. In Cancer Chemoprevention. L Wattenberg, M Lipkin, CW Boone, GJ Kelloff (eds). Boca Raton, Florida, CRC Press, 1992, pp 165-180
26. Ahnen D, Alberts D, Hixson L, Paranka N, Burt R, Panukcu R: The sulfone metabolite of sulindac (FGN-1) inhibits rat colonic carcinogenesis but does not inhibit either prostaglandin synthesis or colonic proliferation. Gastroenterology 108:A444, 1995
27. Hanif R, Pittas A, Feng Y, Koutsos M, Shiff S, Staiano-Coico L, Rigas B: NSAIDs inhibit the growth of colon cancer cell lines by a prostaglandin independent pathway. Gastroenterology 108:A478, 1995
28. Winde G, Schmid KW, Schlegel W, Fischer R, Osswald H, Bunte H: Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Dis Colon Rectum 38:813-830, 1995
29. Nugent KP, Spigelman AD, Phillips RKS: Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Dis Colon Rectum 659-662, 1996
30. Hubbard WC, Litterst CL, Liu MC, Bleecker ER, Eggleston JC, McLemore TL, Boyd MR: Profiling of prostaglandin biosynthesis in biopsy fragments of human lung carcinoma and human lung tissues by capillary gas chromatography-negative ion chemical ionization mass spectrometry. Prostaglandins 32:889-906, 1986
31. 2 in bronchoalveolar fluid from the lower respiratory tract of human subjects by combined capillary gas chromatography-mass spectrometry. Prostaglandins 35:69-81, 1988
32. 2 in rectal mucosa in human subjects: A method study. Cancer Epidemiol Biomarkers Prev 4:239-244, 1995
33. Thorson AG, Lynch HT, Smyrk TC: Rectal cancer in FAP patient after sulindac. Lancet 343;180, 1994
34. Niv Y, Fraser GM: Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 107:854-857, 1994
35. Pasricha PJ, Bedi A, O'Connor K, Rashid A, Akhtar AJ, Zahurak ML, Piantadosi S, Hamilton SR, Giardiello FM: The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 109:994-998, 1996
36. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C, Guillen JM, Brendel K, Gross PH, Sperl G, Ritchie J, Burt RW, Ellsworth L, Ahnen DJ, Pamukeu R: Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57:2909-2915, 1997
37. Thompson HJ, Jiang C, Lu JX, Menta RG, Piazza GA, Paranka NS, Panukcu R, Ahnen DJ: Sulfone metabolite of sulindac inhibits Mammary carcinogenesis. Cancer Research 57:267-271, 1997